ARTICLE | Clinical News

Teflaro ceftaroline regulatory update

November 1, 2010 7:00 AM UTC

FDA approved an NDA from Forest for Teflaro ceftaroline to treat adults with community acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI), including methicillin-resistant Staphylococcus aureus (MRSA). In September, an FDA panel was unanimous that ceftaroline was a safe and effective treatment (see BioCentury, Sept. 13). ...